Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib - Contacts and Locations

Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib

This study is currently recruiting participants.

Study NCT00688766. Last updated on November 12, 2008. Information provided by Infinity Pharmaceuticals

Please refer to this study by its ClinicalTrials.gov identifier: NCT00688766

Contacts


Contact: GIST Phase 3 Team	877-504-INFI	RINGtrialinfo@infi.com

Locations


United States, California
		Recruiting
	Los Angeles, California, United States, 90048
		Recruiting
	Pasadena, California, United States, 91010

United States, Idaho
		Recruiting
	Coeur d'Alene, Idaho, United States, 83814

United States, Illinois
		Recruiting
	Park Ridge, Illinois, United States, 60068

United States, Massachusetts
		Recruiting
	Boston, Massachusetts, United States, 02115

United States, North Carolina
		Recruiting
	New Bern, North Carolina, United States, 28562

United States, Pennsylvania
		Recruiting
	Philadelphia, Pennsylvania, United States, 19046

Sponsors and Collaborators

Infinity Pharmaceuticals

MedImmune LLC

AstraZeneca

Investigators


Study Director:	Robert Shepard, M.D.	Infinity Pharmaceuticals, Inc.

Principal Investigator:	George Demetri, MD	Dana-Farber Cancer Institute